Document is current
Any future updates will be listed below
-
Authors
Nedelcovych, Michael T.
Dash, Ranjeet P.
Wu, Ying
Choi, Eun Yong
Lapidus, Rena S.
Majer, Pavel
Jančařík, Andrej
Abou, Diane
Penet, Marie-France
Nikolopoulou, Anastasia
Amor-Coarasa, Alex
Babich, John
Thorek, Daniel L.
Rais, Rana
Kratochwil, Clemens
Slusher, Barbara S.
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA161056, R01CA201035, R01CA229893, R01CA240711)
IOCB (RVO 61388963)
National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102)
Maryland TEDCO (MII award)
- License Information
-
More Information
Article History
Received: 11 June 2024
Accepted: 16 December 2024
First Online: 2 January 2025
Declarations
:
: No research in the present article involved human participants. All animal experiments were conducted in compliance with National Institutes of Health (NIH) guidelines and with the approval of the Institutional Animal Care and Use Committees at relevant institutions as detailed above.
: Authors BSS, PM, AJ and RR are listed as inventors in patent applications filed by Johns Hopkins Technology Ventures covering novel compositions of 2-PMPA-based prodrugs including JHU-2545. MTN, BSS, RR, and CK are inventors on a method of use patent application filed by Johns Hopkins Technology Ventures covering PSMA normal tissue shielding. MTN, BSS, and RR co-founded Adarga Pharmaceuticals to commercialize these inventions which were licensed to Bayer AG and have received and/or are eligible for related milestone or royalty payments. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. Other authors declare no conflicts of interest exist.
